<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00653120</url>
  </required_header>
  <id_info>
    <org_study_id>40451</org_study_id>
    <nct_id>NCT00653120</nct_id>
  </id_info>
  <brief_title>Bioavailability Study of Propranolol Under Fasting Conditions</brief_title>
  <official_title>Comparative, Randomized, Single-Dose, 2 Way Cross Over Bioavailability Study of Par Propranolol 160 mg With That of Inderal-LA Propranolol 160 mg in Healthy Subjects Under Fasting Conditions.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Par Pharmaceutical, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>SFBC Anapharm</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Par Pharmaceutical, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the single-dose bioavailability of Propranolol 160 Mg ER capsules with Inderal-La
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To compare the single -dose bioavailability of Par Propranolol 160 Mg ER capsules with Wyeth
      Pharmaceuticals, Inderal-LA, Propranolol under fasting conditions.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2005</start_date>
  <completion_date type="Actual">November 2005</completion_date>
  <primary_completion_date type="Actual">November 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate and Extend of Absorption</measure>
    <time_frame>24 Hours</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>To Determine Bioequivalence Under Fasting Conditions</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received Par Products under fasting conditions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects received Wyeth Pharmaceuticals product under fasting conditions</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propranolol</intervention_name>
    <description>ER capsules, 160 mg, single-dose</description>
    <arm_group_label>A</arm_group_label>
    <other_name>Inderal-LA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Inderal-LA</intervention_name>
    <description>ER capsules, 160 mg, single-dose</description>
    <arm_group_label>B</arm_group_label>
    <other_name>Propranolol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects enrolled in the study will be members of the community at large. The
             Recruitment advertisements may use various media types (E.g. ratio, newspapers, SFBC
             Anapharm Website, SFBC Anapharm volunteer's database). Subjects must meet all the
             following criteria in order to be included in the study.

          -  Male and female, non-smoker, 18 years of age and older

          -  Capable of consent

          -  BMI â‰¥ 19.0 and &gt; 30.0 kg/ m2.

        Exclusion Criteria:

          -  Subjects to whom any of the following applies will be excluded from the study.

          -  Clinically significant illness within 4 weeks prior to the administration of the study
             medication

          -  Clinically significant surgery within 4 weeks prior to the administration of the study
             medication.

          -  Any clinically significant abnormality found during medical screening.

          -  Any reason which, in the opinion of the Medical Sub- Investigator, would prevent the
             subject from participating in the study.

          -  Abnormal laboratory tests judged clinically significant.

          -  Positive testing for hepatitis B, hepatitis C, or HIV at screening.

          -  ECG abnormalities (clinically significant) or vital sign abnormalities (systolic blood
             pressure lower than 100 or over 140 mmHg, diastolic blood pressure lower than 60 or
             over 90 mmHg, or heart rate less than 60 or over 100 bpm) at screening.

          -  History of significant alcohol abuse or drug abuse within one year prior to the
             screening visit.

          -  Regular use of alcohol within six months prior to the screening visit (more than
             fourteen units of alcohol per week [ 1 Unit = 150mL of wine, 360 mL of beer, or 45mL
             of 40% alcohol])

          -  Use of soft drugs ( such as marijuana) within 3 months prior to the screening visit or
             hard drugs (such as cocaine, phencyclidine [PCP] and crack) within 1 year prior to the
             screening visit or positive urine drug at screening.

          -  History of allergic reactions to heparin, propranolol, or other related drugs.

          -  Use of any drugs known to induce or inhibit hepatic drug metabolism (examples of
             inducers: barbiturates, carbamazepine, phenytoin,glucocorticoids , omerprazole;
             examples of inhibitors: antidepressants (SSRI), cimetidine, diltiazem, macrolides,
             imidazoles, neuroleptics, verapamil, fluoroquinolones, antihistamines) within 30 days
             prior to administration of the study medication.

          -  Use of an investigational drug or participation in an investigational study within 30
             days prior to administration of the study medication.

          -  Clinically significant history or presence of any clinically significant
             gastrointestinal pathology (e.g. chronic diarrhea, inflammatory bowel diseases),
             unresolved gastrointestinal symptoms (e.g. diarrhea, vomiting), liver or kidney
             disease, or other conditions known as interface with the absorption, distribution,
             metabolism, or excretion of the drug.

          -  Any clinically significant history or presence of clinically significant neurological,
             endocrinal, cardiovascular, pulmonary, hematologic, psychiatric, or metabolic disease.

          -  Use of prescription medication within 14 days prior to administration of a study
             medication or over the counter products (including natural food supplements, vitamins,
             garlic as a supplement) within 7 days prior to administration of study medication,
             except for topical products without systemic absorption and hormonal contraceptive.

          -  Difficulty to swallow study medication.

          -  Use of any tobacco products in the 6 months proceeding drug administration.

          -  Any food allergy, intolerance, restriction or special diet that, in the opinion of the
             Medical Sub- Investigator, could contraindicate the subject's participation in this
             study.

          -  A depot injection or an implant of any drug (other than contraceptives) within 3
             months prior to administration of study medication.

          -  Donation of plasma (500 Ml) within 7 days to drug administration. Donation or loss of
             whole blood (excluding the volume of blood drawn during the screening procedures of
             this study) prior to administration of the study medication as follows.

          -  50mL to 300mL of whole blood within 30 days, 301 mL to 500 ml of whole blood within
             45days or more than 500 mL of whole blood within 56 days prior to drug
             administration..

          -  History bronchial asthma and bronchospastic diseases.

          -  History of known presence of cardiogenic shock, sinus bradycardia, Wolff-Parkinson
             White Syndrome, congestive heart failure or angina.

          -  Clinically significant history of diabetes.

          -  Clinically significant history of hyperthyroidism.

          -  Breast- feeding subject.

          -  Positive urine pregnancy test at screening.

          -  Female subjects of childbearing potential having unprotected sexual intercourse with
             any non- sterile male partner (i.e. male who ahs not been sterilized by vasectomy for
             al least 6 months) within 14 days prior to study drug administration. Acceptable
             methods of contraception:

          -  Intra-uterine contraceptive device (place al least 4 weeks prior to study drug
             administration)

          -  Condom or diaphragm. + spermicide

          -  Hormonal contraceptives (starting al least 4 weeks prior to study administration)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Denis Audet</last_name>
    <role>Principal Investigator</role>
    <affiliation>SFBC Anapharm</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>SFBC Anapharm</name>
      <address>
        <city>Sainte- Foy</city>
        <state>Quebec</state>
        <zip>G1V2K8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>April 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 1, 2008</study_first_submitted>
  <study_first_submitted_qc>April 1, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 4, 2008</study_first_posted>
  <last_update_submitted>April 1, 2008</last_update_submitted>
  <last_update_submitted_qc>April 1, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 4, 2008</last_update_posted>
  <responsible_party>
    <name_title>Dr. Alfred Elvin/ Director Biopharmaceutics</name_title>
    <organization>Par Pharmaceutical, Inc.</organization>
  </responsible_party>
  <keyword>Bioequivalence, Propranolol ER capsules, fasting</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propranolol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

